Daiwa: Lowering the target price of China National Pharmaceutical Group to HK$22.5, lowering profit forecasts.

Morgan Stanley released a report stating that it lowered the profit forecast of China National Pharmaceutical Group Corporation for the years 2025 to 2030 by 1% to 6% due to a downward adjustment in the sales forecast of the medical equipment and pharmaceutical distribution sectors. The target price was also lowered from HK$23 to HK$22.5, with a "hold" rating.